Bioactive secondary metabolites produced by Streptomyces spp.: Overview of antibacterial and anticancer properties | ||||
Microbes and Infectious Diseases | ||||
Articles in Press, Accepted Manuscript, Available Online from 11 February 2025 | ||||
Document Type: Review Article | ||||
DOI: 10.21608/mid.2025.338574.2360 | ||||
![]() | ||||
Authors | ||||
Nadia ZOUGAGH ![]() | ||||
Department of biology, Faculty of Sciences Ben M'Sick, Hassan II University, B.P: 7955, Casablanca, Morocco | ||||
Abstract | ||||
Backgrounf: Actinomycetes thrive in a variety of terrestrial and aquatic environments and are renowned for their ability to generate a wide range of natural products. Among them, Streptomyces species stand out as prolific producers of bioactive molecules (BMs) with significant pharmacological and biotechnological applications. These natural products play a vital role in combating infections and cancers. However, the growing challenges of antibiotic resistance and resistance to cancer treatments underscore the need for continuous discovery and development of new compounds. Streptomyces, a key group within actinomycetes, remains a rich yet underexplored source of secondary metabolites. This review focuses on antibacterial and anticancer BMs produced by Streptomyces, summarizing discoveries since 2006 and exploring both traditional production methods and innovative strategies, including multi-omics, CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats–CRISPR-associated protein) technologies and artificial intelligence. These advancements highlight the potential of Streptomyces to address pressing global health challenges, paving the way for sustainable drug discovery and the development of next-generation therapeutics. Furthermore, the integration of cutting-edge computational tools and synthetic biology approaches holds promise for unlocking the full biosynthetic potential of these microorganisms. | ||||
Keywords | ||||
Streptomyces; bioactive molecules; multi-omics; CRISPR/Cas9 | ||||
Statistics Article View: 351 |
||||